Canada markets closed

  • S&P/TSX
    17,845.91
    -70.29(-0.39%)

  • S&P 500
    3,841.47
    -11.60(-0.30%)

  • DOW
    30,996.98
    -179.02(-0.57%)

Eidos Therapeutics, Inc. (6MX.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
101.000.00 (0.00%)
At close: 2:40PM CET
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2019-12-31
2018-12-31
2017-12-31
Total Revenue
26,691
26,691
0
0
Cost of Revenue
2,500
2,500
-
-
Gross Profit
24,191
24,191
-
-
Operating Expenses
Research Development
46,891
46,891
28,539
9,286
Selling General and Administrative
17,751
17,751
9,240
2,730
Total Operating Expenses
64,642
64,642
37,779
12,016
Operating Income or Loss
-40,451
-40,451
-37,779
-12,016
Interest Expense
327
327
-
-
Total Other Income/Expenses Net
2,943
2,943
-2,946
75
Income Before Tax
-37,835
-37,835
-40,725
-11,941
Income from Continuing Operations
-37,835
-37,835
-40,725
-11,941
Net Income
-37,835
-37,835
-40,725
-11,941
Net Income available to common shareholders
-37,835
-37,835
-40,725
-11,941
Basic EPS
-
-1.03
-1.86
-0.93
Diluted EPS
-
-1.03
-1.86
-0.93
Basic Average Shares
-
36,625
21,367
12,777
Diluted Average Shares
-
36,625
21,367
12,777
EBITDA
-
-37,431
-37,723
-12,012